Biomea Fusion, Inc. (BMEA)
2.03
+0.12
(+6.28%)
USD |
NASDAQ |
Sep 04, 16:00
2.03
0.00 (0.00%)
After-Hours: 20:00
Biomea Fusion Net Income (Quarterly) : -8.328M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.328M |
| March 31, 2026 | -12.42M |
| December 31, 2025 | 4.612M |
| September 30, 2025 | -16.41M |
| June 30, 2025 | -20.74M |
| March 31, 2025 | -29.26M |
| December 31, 2024 | -29.30M |
| September 30, 2024 | -32.79M |
| June 30, 2024 | -37.28M |
| March 31, 2024 | -39.06M |
| December 31, 2023 | -34.88M |
| September 30, 2023 | -28.43M |
| June 30, 2023 | -24.89M |
| Date | Value |
|---|---|
| March 31, 2023 | -29.05M |
| December 31, 2022 | -25.31M |
| September 30, 2022 | -22.89M |
| June 30, 2022 | -17.26M |
| March 31, 2022 | -16.37M |
| December 31, 2021 | -14.71M |
| September 30, 2021 | -12.61M |
| June 30, 2021 | -8.399M |
| March 31, 2021 | -5.852M |
| December 31, 2020 | -3.498M |
| September 30, 2020 | -1.135M |
| June 30, 2020 | -0.293M |
| March 31, 2020 | -0.398M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| REGENXBIO, Inc. | 22.71M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 8.328M |
| EPS Diluted (Quarterly) | -0.1151 |
| Enterprise Value | 112.83M |
| Earnings Yield | -24.49% |
| Normalized Earnings Yield | -34.37 |